{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:55:44Z","timestamp":1780491344459,"version":"3.54.1"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.atherosclerosis.2016.09.001","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T20:13:05Z","timestamp":1473451985000},"page":"134-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors"],"prefix":"10.1016","volume":"256","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3786-0883","authenticated-orcid":false,"given":"Marcello","family":"Arca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.09.001_bib1","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment","volume":"111","author":"Rader","year":"2003","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib2","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"2863","article-title":"Familial hypercholesterolemia","author":"Goldstein","year":"2001"},{"issue":"4746","key":"10.1016\/j.atherosclerosis.2016.09.001_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A\u00a0receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"issue":"48","key":"10.1016\/j.atherosclerosis.2016.09.001_bib4","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.09.001_bib5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MOL.0b013e3283532947","article-title":"Post-transcriptional regulation of lipoprotein receptors by the E3-ubiquitin ligase inducible degrader of the low-density lipoprotein receptor","volume":"23","author":"Sorrentino","year":"2012","journal-title":"Curr. Opin. Lipidol."},{"issue":"5520","key":"10.1016\/j.atherosclerosis.2016.09.001_bib6","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1060458","article-title":"Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein","volume":"292","author":"Garcia","year":"2001","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.09.001_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.09.001_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat. Clin. Pract. Cardiovasc Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.09.001_bib9","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1172\/JCI109490","article-title":"Metabolic studies in familial hypercholesterolemia. Evidence for a gene-dosage effect in\u00a0vivo","volume":"64","author":"Bilheimer","year":"1979","journal-title":"J.\u00a0Clin. Investig."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2016.09.001_bib10","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1503\/cmaj.051313","article-title":"Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease","volume":"174","author":"Yuan","year":"2006","journal-title":"CMAJ"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.09.001_bib11","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM198709173171204","article-title":"Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia","volume":"317","author":"Hobbs","year":"1987","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.09.001_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/01.ATV.9.2.211","article-title":"Homozygous familial hypercholesterolemia among French Canadians in Quebec Province","volume":"9","author":"Moorjani","year":"1989","journal-title":"Arteriosclerosis"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2016.09.001_bib13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.ejhg.5201151","article-title":"Founder mutations among the Dutch","volume":"12","author":"Zeegers","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.09.001_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2015.04.809","article-title":"Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology","volume":"241","author":"De Backer","year":"2015","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.09.001_bib15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jacl.2015.07.005","article-title":"Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit","volume":"9","author":"Pang","year":"2015","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.09.001_bib16","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2016.09.001_bib17","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","article-title":"Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217","volume":"37","author":"Benn","year":"2016","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.09.001_bib18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2013.12.020","article-title":"Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers","volume":"233","author":"Besseling","year":"2014","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.09.001_bib19","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.115.018791","article-title":"Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES)","volume":"133","author":"de Ferranti","year":"2016","journal-title":"Circulation"},{"issue":"45","key":"10.1016\/j.atherosclerosis.2016.09.001_bib20","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.09.001_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2003.11.010","article-title":"Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia","volume":"173","author":"Civeira","year":"2004","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.09.001_bib22","article-title":"Mortality among patients with familial hypercholesterolemia: a registry-based study in norway, 1992-2010","volume":"3","author":"Mundal","year":"2014","journal-title":"J.\u00a0Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.09.001_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18553\/jmcp.2013.19.2.139","article-title":"Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on familial hypercholesterolemia","volume":"19","author":"Robinson","year":"2013","journal-title":"J.\u00a0Manag. Care Pharm."},{"issue":"6807","key":"10.1016\/j.atherosclerosis.2016.09.001_bib24","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia","volume":"303","author":"Scientific Steering Committee on behalf of the Simon Broome Register Group","year":"1991","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2016.09.001_bib25","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI107332","article-title":"Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia","volume":"52","author":"Goldstein","year":"1973","journal-title":"J.\u00a0Clin. Investig."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.09.001_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9149(98)00328-2","article-title":"Relative contribution of low-density lipoprotein receptor and lipoprotein lipase gene mutations to angiographically assessed coronary artery disease among French Canadians","volume":"82","author":"Gaudet","year":"1998","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield of sequencing familial Hypercholesterolemia genes in patients with severe Hypercholesterolemia","author":"Khera","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.09.001_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on familial hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"13","key":"10.1016\/j.atherosclerosis.2016.09.001_bib30","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/eurheartj\/eht015","article-title":"Diagnosis and treatment of familial hypercholesterolaemia","volume":"34","author":"Hovingh","year":"2013","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2016.09.001_bib31","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.09.001_bib32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9149(93)90155-6","article-title":"Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics","volume":"72","author":"Williams","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib33","series-title":"Familial Hypercholesterolemia. Report of a Second WHO Consultation","author":"Group WHOFHC","year":"1998"},{"issue":"18","key":"10.1016\/j.atherosclerosis.2016.09.001_bib34","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/eurheartj\/ehl113","article-title":"Diagnosing familial hypercholesterolaemia: the relevance of genetic testing","volume":"27","author":"van Aalst-Cohen","year":"2006","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.09.001_bib35","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00439-001-0628-8","article-title":"The molecular basis of familial hypercholesterolemia in The Netherlands","volume":"109","author":"Fouchier","year":"2001","journal-title":"Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib36","first-page":"35","article-title":"Linee guida cliniche per la prevenzione della cardiopatia ischemica nella ipercolesterolemia familiare: una patologia sotto-diagnosticata e sotto-trattata","author":"Averna","year":"2013","journal-title":"La Soc. Ital. lo Studio dell\u2019Arteriosclerosi Consens."},{"issue":"3 Suppl","key":"10.1016\/j.atherosclerosis.2016.09.001_bib37","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jacl.2011.03.452","article-title":"Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on familial hypercholesterolemia","volume":"5","author":"Hopkins","year":"2011","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"Pt 4","key":"10.1016\/j.atherosclerosis.2016.09.001_bib38","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1469-1809.2008.00436.x","article-title":"Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database","volume":"72","author":"Leigh","year":"2008","journal-title":"Ann. Hum. Genet."},{"issue":"9874","key":"10.1016\/j.atherosclerosis.2016.09.001_bib39","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study","volume":"381","author":"Talmud","year":"2013","journal-title":"Lancet"},{"issue":"9874","key":"10.1016\/j.atherosclerosis.2016.09.001_bib40","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(13)60187-7","article-title":"Polygenic familial hypercholesterolaemia: does it matter?","volume":"381","author":"Stein","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.09.001_bib41","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/gim.2013.55","article-title":"The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia","volume":"15","author":"Vandrovcova","year":"2013","journal-title":"Genet. Med."},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib42","series-title":"Elucigene FH20 and LIPOchip for the Diagnosis of Familial Hypercholesterolaemia: Guidance (DG2)","author":"National Institute for Health and Clinical Excellence (NICE)","year":"2011"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.09.001_bib43","doi-asserted-by":"crossref","first-page":"e9220","DOI":"10.1371\/journal.pone.0009220","article-title":"Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal","volume":"5","author":"Huijgen","year":"2010","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.09.001_bib44","first-page":"26","article-title":"Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening","volume":"11","author":"Leren","year":"2008","journal-title":"Community Genet."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.09.001_bib45","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/heartjnl-2015-308824","article-title":"A\u00a0new electronic screening tool for identifying risk of familial hypercholesterolaemia in general practice","volume":"102","author":"Troeung","year":"2016","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2016.09.001_bib46","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/2047487314533218","article-title":"Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation","volume":"22","author":"Watts","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.09.001_bib47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosis.2014.12.036","article-title":"Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience","volume":"239","author":"Bell","year":"2015","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.09.001_bib48","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/01.mol.0000174152.76554.d6","article-title":"Implementation of cascade testing for the detection of familial hypercholesterolaemia","volume":"16","author":"Hadfield","year":"2005","journal-title":"Curr. Opin. Lipidol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.09.001_bib49","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/01.ATV.0000051874.51341.8C","article-title":"Systematic family screening for familial hypercholesterolemia in Iceland","volume":"23","author":"Thorsson","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2016.09.001_bib50","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/hrt.2010.213975","article-title":"Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies","volume":"97","author":"Nherera","year":"2011","journal-title":"Heart"},{"issue":"7254","key":"10.1016\/j.atherosclerosis.2016.09.001_bib51","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/bmj.321.7254.148","article-title":"Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study","volume":"321","author":"Neil","year":"2000","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.09.001_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A\u00a0review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia","volume":"168","author":"Marks","year":"2003","journal-title":"Atherosclerosis"},{"issue":"Suppl","key":"10.1016\/j.atherosclerosis.2016.09.001_bib53","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib54","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.116.001381","article-title":"Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH Registry","author":"deGoma","year":"2016","journal-title":"Circ. Cardiovasc Genet."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.09.001_bib55","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.atherosclerosis.2013.01.007","article-title":"Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy","volume":"227","author":"Bertolini","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib56","unstructured":"Agenzia Italia per il Farmaco. Determinazione AIFA 19.06.2014, n.617. Gazzetta Ufficiale n. 156 dell\u2019 8.7.2014: modifica alla nota 13 di cui alla determina del 26.3.20132014."},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib57","article-title":"Official site of the Lazio region","author":"Region","year":"2015","journal-title":"Hypercholesterolemia Policy"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.09.001_bib58","first-page":"3","article-title":"ANMCO\/ISS\/AMD\/ANCE\/ARCA\/FADOI\/<BR>GICR-IACPR\/SICI-GISE\/SIBioC\/SIC\/SICOA\/<BR>SID\/SIF\/SIMEU\/SIMG\/SIMI\/SISA Consensus document. Hypercholesterolemia and cardiovascular risk: diagnostic and therapeutic pathways in Italy","volume":"17","author":"Gulizia","year":"2016","journal-title":"G.\u00a0Ital. Cardiol. (Rome)"},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib59","first-page":"41","article-title":"La diagnosi delle principali dislipidemie in Medicina Generale","volume":"48","author":"Filippi","year":"2010","journal-title":"Sintesi la Med. Gen. Ital. \u2013 Aggiornamento"},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib60","series-title":"Online il questionario di Cittadinanzattiva \u201cColesterolo, una questione di famiglia\u201d","year":"2015"},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib61","author":"Italian Society of Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.09.001_bib62","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib63","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"issue":"21","key":"10.1016\/j.atherosclerosis.2016.09.001_bib64","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur. Heart J."},{"issue":"9256","key":"10.1016\/j.atherosclerosis.2016.09.001_bib65","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(00)04053-8","article-title":"Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial","volume":"357","author":"Smilde","year":"2001","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2016.09.001_bib66","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.09.001_bib67","doi-asserted-by":"crossref","first-page":"e16721","DOI":"10.1371\/journal.pone.0016721","article-title":"Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated","volume":"6","author":"Leren","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib68","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1476-511X-10-94","article-title":"Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish familial Hypercholesterolemia longitudinal cohort Study (SAFEHEART)","volume":"10","author":"Mata","year":"2011","journal-title":"Lipids Health Dis."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.09.001_bib69","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.09.001_bib70","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.amjcard.2003.08.009","article-title":"Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia","volume":"92","author":"Stein","year":"2003","journal-title":"Am. J. Cardiol."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2016.09.001_bib71","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.09.001_bib72","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/humu.22721","article-title":"Functional characterization and classification of frequent low-density lipoprotein receptor variants","volume":"36","author":"Etxebarria","year":"2015","journal-title":"Hum. Mutat."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.09.001_bib73","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.amjcard.2011.09.019","article-title":"Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia","volume":"109","author":"Kawashiri","year":"2012","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.09.001_bib74","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.amjcard.2011.03.027","article-title":"Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades","volume":"108","author":"Elis","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib75","first-page":"864317","article-title":"Usefulness of lipid apheresis in the treatment of familial hypercholesterolemia","volume":"2014","author":"Lui","year":"2014","journal-title":"J.\u00a0Lipids"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2016.09.001_bib76","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11886-016-0743-8","article-title":"Future lipid-altering therapeutic options targeting residual cardiovascular risk","volume":"18","author":"Farnier","year":"2016","journal-title":"Curr. Cardiol. Rep."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.09.001_bib77","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/phar.1441","article-title":"Novel treatments for familial hypercholesterolemia: pharmacogenetics at work","volume":"34","author":"Marbach","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.09.001_bib78","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/phar.1672","article-title":"Therapeutic management of familial hypercholesterolemia: current and emerging drug therapies","volume":"35","author":"Patel","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/TACG.S44315","article-title":"The genetics of familial hypercholesterolemia and emerging therapies","volume":"8","author":"Vogt","year":"2015","journal-title":"Appl. Clin. Genet."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.09.001_bib80","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","article-title":"Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia","volume":"115","author":"Ballantyne","year":"2015","journal-title":"Am. J. Cardiol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.09.001_bib81","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nrcardio.2014.169","article-title":"Dyslipidaemia: evolocumab lowers LDL cholesterol","volume":"11","author":"Huynh","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.09.001_bib82","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2217\/fca.13.107","article-title":"Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody","volume":"10","author":"Roth","year":"2014","journal-title":"Future Cardiol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.09.001_bib83","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.09.001_bib84","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J.\u00a0Lipid Res."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.09.001_bib85","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCRESAHA.113.302655","article-title":"Loss of plasma proprotein convertase subtilisin\/kexin 9 (PCSK9) after lipoprotein apheresis","volume":"113","author":"Tavori","year":"2013","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2016.09.001_bib86","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11883-016-0604-3","article-title":"Statins and their effect on PCSK9-Impact and clinical relevance","volume":"18","author":"Taylor","year":"2016","journal-title":"Curr. Atheroscler. Rep."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.09.001_bib87","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11883-013-0310-3","article-title":"Potential of proprotein convertase subtilisin\/kexin type 9 based therapeutics","volume":"15","author":"Stein","year":"2013","journal-title":"Curr. Atheroscler. Rep."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.09.001_bib88","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9836","key":"10.1016\/j.atherosclerosis.2016.09.001_bib89","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib90","unstructured":"Ginsberg H, Rader DJ, Raal FJ, Guyton JR, Lorenzato C, Pordy R, et\u00a0al, editors. ODYSSEY HIGH FH: Efficacy and Safety of Alirocumab in Patients With Severe Heterozygous Familial Hypercholesterolemia. Presented at the American Heart Association Scientific Sessions; Chicago, Illinois; 15\u201319 November 2014. Accessed at http:\/\/my.americanheart.org\/idc\/groups\/ahamah-public\/@wcm\/@sop\/@scon\/documents\/downloadable\/ucm_469651.pdf (Accessed 19.11.14). 2014 15-19 November."},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib91","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv370","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","author":"Kastelein","year":"2015","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.09.001_bib92","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10557-014-6523-z","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies","volume":"28","author":"Kastelein","year":"2014","journal-title":"Cardiovasc Drugs Ther."},{"issue":"16","key":"10.1016\/j.atherosclerosis.2016.09.001_bib93","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"20","key":"10.1016\/j.atherosclerosis.2016.09.001_bib94","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"issue":"9965","key":"10.1016\/j.atherosclerosis.2016.09.001_bib95","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"9965","key":"10.1016\/j.atherosclerosis.2016.09.001_bib96","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2016.09.001_bib97","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.09.001_bib98","unstructured":"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003882\/WC500194524.pdf. (accessed 25.08.16)."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.09.001_bib99","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40273-015-0355-y","article-title":"PCSK9 inhibitors: a technology worth paying for?","volume":"34","author":"Weintraub","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.09.001_bib100","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ahj.2014.09.001","article-title":"Reducing the burden of disease and death from familial hypercholesterolemia: a call to action","volume":"168","author":"Knowles","year":"2014","journal-title":"Am. Heart J."},{"issue":"19","key":"10.1016\/j.atherosclerosis.2016.09.001_bib101","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","article-title":"The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies","volume":"63","author":"Sniderman","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.09.001_bib102","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4070\/kcj.2013.43.6.363","article-title":"Familial hypercholesterolemia and the atherosclerotic disease","volume":"43","author":"Kim","year":"2013","journal-title":"Korean Circ. J."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.09.001_bib103","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/00325481.2015.998987","article-title":"Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin\/kexin type 9 monoclonal antibody: a phase II pooled analysis","volume":"127","author":"Koren","year":"2015","journal-title":"Postgrad. Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016313156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016313156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T06:26:40Z","timestamp":1568356000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915016313156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":103,"alternative-id":["S0021915016313156"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.09.001","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}